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how High-Density Lipoprotein Cholesterol (HDL-C)
ow HDL-C has been established as a cardiovascular risk
actor at least since the Framingham study observation of
significant inverse relationship between HDL-C and
oronary heart disease (CHD) in 1977 (1). Since then,
ultiple prospective epidemiological studies have dem-
nstrated this inverse relationship (1–9). The mechanism
f this increased risk has been attributed to multiple
actors including impaired reverse cholesterol transport,
denosine triphosphatase–binding cassette transporter,
nd reduced oxidative protection.
See page 1238
This inverse relationship between low HDL-C and
ncreased risk has also been attributed to a specific high-
ensity lipoprotein (HDL) subclass, described by various
aboratory techniques as HDL2, HDL2b, alpha1 HDL,
nd LpAI (10). Differences in HDL subclass distributions
n blood were first described by Gofman et al. (11,12) in
954 using analytic ultracentrifugation (11,12). They noted
hat the concentrations of the more buoyant particles
HDL2) were 50% higher in women than in men. Later, in
966, they reported that baseline HDL mass concentrations
ere 32% lower for HDL2 and 8% lower for HDL3 (the
ess buoyant particles) in patients who had CHD develop
uring 10 years of follow-up compared with patients who
id not (13). The HDL subclasses appear to have a
ifferential effect on lipoprotein oxidative protection (14).
xidation, Paraoxonase, and CHD Risk
odification, or oxidation, of apoproteins may contribute
o atherosclerosis in humans. Oxidation of apoprotein B has
een shown to result in a modified low-density lipoprotein
m-LDL) particle that is taken up rapidly by a scavenger
eceptor on tissue macrophages, resulting in atherogenic
oam cell formation, inhibition of macrophage egress from
issue, and damage to the endothelial border that results in
therosclerosis in animal models (15). Incubation of LDL
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theH
merican College of Cardiology.
From Celera Inc. Genetics, Alameda, California.ith cultured endothelial cells results in a modified low-
ensity lipoprotein (m-LDL) that is taken up by macro-
hages 3 to 10 times more rapidly than native LDL,
esulting in atherogenic foam cell formation (16,17). This
-LDL undergoes many structural changes, most of
hich depend on peroxidation of polyunsaturated fatty
cids in the LDL lipids that can be inhibited by vitamin E
18,19). In plasma, aldehydes (namely, malondialdehyde or
-hydroxynonenal) are generated by peroxidation of poly-
nsaturated fatty acids, which are part of LDL phospholip-
ds. These aldehydes may alter lysine residues of apoprotein
and result in m-LDL (19,20). Once the LDL contains
atty acid lipid peroxides, a propagation follows that ampli-
es the number of free radicals and leads to extensive
ragmentation of the fatty acid chains (21).
Paraoxonase (PON) is an enzyme initially of interest in
he field of toxicology because it is an “A” esterase and
ydrolyzes organophosphate compounds used as insecti-
ides and nerve gases (22). PON is associated with HDL
articles, and in sheep, most of the PON activity is
ssociated with the apolipoproteinAI-only particle (23).
hus, part of the protective effect of some, but perhaps not
ll, HDL particles may be the association of PON and its
utative role in decreasing lipid peroxide accumulation on
DL particles (24). The HDL from transgenic mice lacking
ON-1 fails to protect LDL against oxidative modification.
hus, PON-1 may be a determinant of resistance to the
evelopment of atherosclerosis by protecting lipoproteins
gainst oxidative modification, perhaps by hydrolyzing
hospholipid and cholesteryl-ester hydroperoxides.
ON and HDL Link
oth PON-1 and PON-3 reside on HDL particles (25). All
are associated with oxidative protection. The PON-1
ctivity is associated with HDL2 and may be a contributing
actor to the cardioprotection attributed to elevated HDL2
evels (26).
ON Polymorphisms and Atherosclerosis
he PON family is made up of 3 related genes termed
ON-1, PON-2, and PON-3 that reside on chromosome
q21.3 (27). The PON-1 is bound to HDL and appears to
ydrolyze inflammatory phospholipids in both LDL and
DL particles, and plays a role in physiologic anti-
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September 29, 2009:1246–8 Cardiovascular Event Risk: HDL and PONnflammatory activity (28,29). There are 3 common PON-1
olymorphisms: L55M, Q192R, and the promoter poly-
orphism T(107)C (30).
PON polymorphisms have been associated with CHD
isk in some, but not all, investigations. Serrato and Marian
31) described an association between HUMPONA and
HD in 1995. Subsequently, a plethora of investigations
nd associations have been reported (32). In the Nurses’
ealth and Health Professionals Follow-up Study, the
ON-1 polymorphisms Q192R and L55M were not asso-
iated with increased CHD risk (33).
The lack of clarity in the association of PON-1 polymor-
hisms and CHD risk may, in part, be due to the physio-
ogic role of PON, which may be to play a minor role in the
arly pathogenesis of CHD but a more powerful role in the
nteraction with lipid and glucose metabolism and the later
acrovascular aspects of atherosclerosis (34). The likelihood
f severe stenosis has been reported to be greater in CHD
atients with hyperglycemia and serum PON-1 activity
35). Differences in genotype distribution may be related to
everity of CHD in patients with established CHD (36).
moking may be a contributing factor, because the North-
ick Park Heart Study II reported that the L55M and
192R genotype did not differ between cases and control
ubjects but CHD risk associated with smoking was signif-
cantly modified by the L55M genotype (37). Ethnic
ifferences may also play a role, as it has been reported that
n a Turkish patient population PON-1 L55M was associ-
ted with CHD but not PON-1 Q192R (38). The PON-1
ln192Arg SNP has been associated with a significantly
ncreased risk of stroke (39).
Some uncertainty exists in the relationship between
ON polymorphisms and PON concentration or activity.
n case-control studies, serum PON-1 concentration and
ctivity were found to be decreased in CHD independent
f the PON-1 polymorphism, and in diabetes mellitus,
erum PON-1 specific activity decrease is also indepen-
ent of the PON-1 genetic polymorphism (40).
omments on the Current Article
ithin the context of this lack of clarity in regard to PON
olymorphisms and CHD risk, the article by Regieli et al.
41) in this issue of the Journal addresses a clinically
mportant issue, which is the importance of HDL and
everse cholesterol transport and the physiologic and genetic
ttributes that may confer risk reduction benefit. The
EGRESS (REgression GRowth Evaluation Statin Study)
tudy population is well described and has been utilized to
ddress other medically relevant questions. The role of
xidative protection attributed to PON residing on HDL
articles has been explored by other investigators. What is
ew is the relationship of PON-1 genetic variants and pro-
pective long-term clinical outcome in well-characterized male
aucasian CHD patients. Their data indicate a significant
ncrease in CHD death in the 14% of the population with theM L55M genotype. Furthermore, there was an allele-dose
ffect in that the 10-year risk of CHD death was 4.6% in
55 homozygotes, 7.1% in heterozygotes, and 10.9% in
5M homozygotes. Importantly, this relationship was un-
hanged when corrected for HDL-C, LDL cholesterol,
riglycerides, and current smoking status, suggesting that
he PON-1 genotype may be an independent risk factor for
HD death. Some conflict may exist with other case-
ontrol studies but is adequately addressed by Regieli et al.
41). This study contributes new knowledge regarding the
isk of CHD death in male CHD patients and the relation-
hip of common PON polymorphisms.
eprint requests and correspondence: Dr. H. Robert Superko,
elera Inc. Genetics, 1401 Harbor Bay Parkway, Alameda, Cali-
ornia 94502. E-mail: robert.superko@celera.com.
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